Legend Biotech Corp. ADR (LEGN) News
Filter LEGN News Items
LEGN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
LEGN News Highlights
- LEGN's 30 day story count now stands at 2.
- Over the past 14 days, the trend for LEGN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- ASH are the most mentioned tickers in articles about LEGN.
Latest LEGN News From Around the Web
Below are the latest news stories about LEGEND BIOTECH CORP that investors may wish to consider to help them evaluate LEGN as an investment opportunity.
13 High Growth Healthcare Stocks to BuyIn this article, we will take a look at 13 high growth healthcare stocks to buy. To skip our analysis of the recent market activity, you can go directly to see the 5 Best High Growth Healthcare Stocks to Buy. For the purpose of this article, we have defined high growth stocks as stocks that […] |
Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)SOMERSET, N.J., December 12, 2023--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life-threatening diseases, announced today patient-reported outcome (PRO) data from the Phase 3 CARTITUDE-4 study from an oral presentation at the 2023 American Society of Hematology (ASH) Annual Meeting (Abstract #1063). These data showed clinically meaningful improvement in health-related quality of |
CAR T-Cell Therapies Under FDA Watch on Reports of MalignanciesThe FDA has undertaken an investigation of T-cell malignancies in patients undergoing CAR T-cell therapy treatment. Therapies from NVS, BMY and GILD are under the spotlight. |
FDA Looking Into All Approved CAR T Therapies on Risk of Cancer in White Blood CellsThe U.S. Food and Drug Administration is investigating certain CAR T cancer therapies based on reports that they might cause a type of white blood cell to become cancerous in patients who received the treatment. |
Legend Biotech Corporation (NASDAQ:LEGN) Q3 2023 Earnings Call TranscriptLegend Biotech Corporation (NASDAQ:LEGN) Q3 2023 Earnings Call Transcript November 20, 2023 Legend Biotech Corporation beats earnings expectations. Reported EPS is $-0.17, expectations were $-0.56. Operator: Good day, ladies and gentlemen. Thank you for standing by. Welcome to Legend Biotech Reports Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in […] |
There's Reason For Concern Over Legend Biotech Corporation's (NASDAQ:LEGN) PriceLegend Biotech Corporation's ( NASDAQ:LEGN ) price-to-sales (or "P/S") ratio of 46.8x might make it look like a strong... |
The Zacks Analyst Blog Highlights Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta TherapeuticsGilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics are part of the Zacks top Analyst Blog. |
Q3 2023 Legend Biotech Corp Earnings CallQ3 2023 Legend Biotech Corp Earnings Call |
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024We have narrowed our search to five biotech stocks with strong potential for 2024. These are: LEGN, BGNE, GILD, EXAS, SRPT. |
Legend Biotech Reports Third Quarter 2023 Results and Recent HighlightsSOMERSET, N.J., November 20, 2023--Legend Biotech announced third-quarter 2023 financial results. |